Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Stomach Neoplasms 6Neoplasms 3Small Cell Lung Carcinoma 2Recurrence 2Lymphoma 2Non-Erosive Reflux Disease 1Melanoma 1Lymphoma, Mantle-Cell 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Hematologic Neoplasms 1Helicobacter Infections 1Gastrointestinal Hemorrhage 1Gastroesophageal Reflux 1Gastritis, Atrophic 1Dyspepsia 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1COVID-19 1Barrett Esophagus 1Atrophy 1Advanced Solid Tumors 1Advanced Solid Malignancies 1Adenocarcinoma 1Acrocephalosyndactylia 1

Interventions

Standard of Care 8Surveys and Questionnaires 7COVID-19 Vaccines 6Blood Specimen Collection 6BNT162 Vaccine 6Specimen Handling 52019-nCoV Vaccine mRNA-1273 5Hydroxychloroquine 4Surgical Procedures, Operative 3Practice Guidelines as Topic 3tocilizumab 2sotrovimab 2sinovac COVID-19 vaccine 2cilgavimab and tixagevimab drug combination 2Sodium Chloride 2Pandemic Preparedness 2Data Collection 2CVnCoV COVID-19 vaccine 2COH04S1 COVID-19 vaccine 2Azithromycin 2selinexor 1remdesivir 1regorafenib 1proxalutamide 1palbociclib 1ogalvibart 1monalizumab 1lenzilumab 1heterologous prime boost COVID-19 vaccination 1crexavibart 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
COVID-19 × Rabeprazole × Clear all
NCT04564040 2020-12-29

A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole

AstraZeneca

Phase 1 Completed
20 enrolled
Lymphoid

COVID-19, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡